4,426 results match your criteria Biology of Blood and Marrow Transplantation[Journal]


Autologous Transplantation for Male Germ Cell Tumors: Improved Outcomes over 3 decades.

Biol Blood Marrow Transplant 2019 Feb 19. Epub 2019 Feb 19.

Medical College of Wisconsin, Milwaukee, WI.

Purpose: The curative potential of autologous hematopoietic cell transplantation (autoHCT) for male germ cell tumors (GCT) is well established. Optimal timing and number (single, ST vs. tandem, TT vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.015DOI Listing
February 2019

AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR TREATMENT-REFRACTORY RELAPSING MULTIPLE SCLEROSIS: POSITION STATEMENT FROM THE AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION.

Biol Blood Marrow Transplant 2019 Feb 19. Epub 2019 Feb 19.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Multiple sclerosis (MS) is a chronic, disabling, immune-mediated, central nervous system demyelinating and degenerative disease. Approved disease modifying therapies may be incompletely effective in some patients with highly active relapsing disease and high risk of disability. Immunoablative or myeloablative therapy followed by autologous hematopoietic cell transplantation (AHCT) has been investigated in retrospective studies, clinical trials, and meta-analyses/systematic reviews as an approach to address this unmet clinical need. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.014DOI Listing
February 2019

Risk factors and predictive scoring system for post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation.

Biol Blood Marrow Transplant 2019 Feb 19. Epub 2019 Feb 19.

Department of Oncology and Hematology, Shimane University Hospital, Izumo, Japan. Electronic address:

We analyzed data of 64,539 consecutive patients in the national Japanese transplant registry, including 40,195 after allogeneic stem cell transplantation, 24,215 after autologous stem cell transplantation, and 129 after syngeneic stem cell transplantation, and 299 developed Epstein-Barr virus positive post-transplant lymphoproliferative disorder. The probability at 2 years was 0.79% after allogeneic transplantation, 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.016DOI Listing
February 2019

Utilization and outcomes of fertility preservation techniques in women undergoing allogeneic hematopoietic cell transplant.

Biol Blood Marrow Transplant 2019 Feb 14. Epub 2019 Feb 14.

Division of Hematology, Mayo Clinic, Rochester MN. Electronic address:

Iatrogenic menopause with consequent infertility is a major complication in reproductive aged women undergoing hematopoietic cell transplantation (HCT). Recent guidelines recommend a discussion of the possibility of infertility and the options for fertility preservation as part of informed consent before initiation of any cancer-directed therapy, including HCT. Women aged 15-49 years at the time of allogeneic HCT, between the years 2001 and 2017, were identified from the Mayo Clinic Rochester institutional HCT database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.013DOI Listing
February 2019
2 Reads

Hematopoietic stem cell transplantation for mucopolysaccharidoses; past, present, and future.

Biol Blood Marrow Transplant 2019 Feb 14. Epub 2019 Feb 14.

Nemours/ Alfred I. duPont Hospital for Children, Wilmington, DE, USA; Department of Pediatrics, Shimane University Faculty of Medicine, Shimane, Japan; Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan; Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA. Electronic address:

Allogenic hematopoietic stem cell transplantation (HSCT) has been shown to be a treatment option for a selected group of patients with mucopolysaccharidoses (MPS) (MPS I, II, IVA, VI, and VII). Early diagnosis and timely referral to an expert in MPS are critical, followed by a complete examination and evaluation with a multidisciplinary team, including a transplant physician. Treatment recommendations for MPS are based on multiple factors such as biological, sociological, and financial effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.012DOI Listing
February 2019
1 Read

Non-myeloablative Matched Sibling Donor Hematopoietic Cell Transplantion in Children and Adolescents with Sickle Cell Disease.

Biol Blood Marrow Transplant 2019 Feb 14. Epub 2019 Feb 14.

Section of Oncology/BMT, Departments of Oncology and Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Canada.

Sickle cell disease (SCD) is a potentially debilitating hemoglobinopathy associated with early mortality. The only established curative therapy is hematopoietic cell transplantation (HCT)with a matched sibling donor (MSD). The National Institutes of Health (NIH) nonmyeloablative regimen of alemtuzumab/300 cGy total body irradiation and prolonged sirolimus exposure for graft-versus-host disease (GVHD) prophylaxis was administered to 16 children and adolescents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.011DOI Listing
February 2019

Improved survival after cord blood transplantation: single center experience in pediatric patients over a two-decade period.

Biol Blood Marrow Transplant 2019 Feb 13. Epub 2019 Feb 13.

Clinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA; Department of Medicine, University of Washington, Seattle, WA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.010DOI Listing
February 2019

Development of pre-engraftment syndrome, but not acute graft-versus-host disease, reduces relapse rate of acute myeloid leukemia after single cord blood transplantation.

Biol Blood Marrow Transplant 2019 Feb 13. Epub 2019 Feb 13.

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

The different effects of pre-engraftment syndrome (PES) and acute graft-versus-host disease (GVHD) on transplant outcomes after cord blood transplantation (CBT) are unclear. We retrospectively evaluated the impact of PES and acute GVHD on relapse and survival after single CBT for 138 adult patients with hematological malignancies in our institute between 2004 and 2016. Multivariate analysis demonstrated that development of grade III to IV acute GVHD, particularly gut or liver involvement of acute GVHD, significantly contributed to higher non-relapse mortality (P<0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.007DOI Listing
February 2019
1 Read

Barriers to Allogeneic Hematopoietic Stem Cell Transplant for Human T-Cell Lymphotropic Virus 1 associated Adult T-Cell Lymphoma-Leukemia in the United States: Experience from a large cohort in a major tertiary center.

Biol Blood Marrow Transplant 2019 Feb 12. Epub 2019 Feb 12.

Department of Medical Oncology, Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, NY; Department of Medicine, Division of HOT, University of Minnesota, Minneapolis, MN. Electronic address:

In the United States (U.S.), Adult T-Cell Lymphoma-Leukemia (ATLL) carries a dismal prognosis and mainly affects immigrants from Human T-Cell Lymphotropic Virus 1 (HTLV-1) endemic areas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.004DOI Listing
February 2019

The Roles of FDG PET-CT in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy Treating Patients with Non-Hodgkin Lymphoma.

Biol Blood Marrow Transplant 2019 Feb 12. Epub 2019 Feb 12.

PET-CT Center, the First Affiliated Hospital, Zhejiang University. Electronic address:

Background: CD19-targeting chimeric antigen receptor (CAR) T cell therapy has shown great efficacy in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), but has been associated with serious adverse effects such as cytokine release syndrome (CRS). It has been speculated that NHL baseline disease burden might affect clinical outcome and CRS, but such assumption has not been explored in detail. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG), as measured by FDG PET-CT, are quantitative indicators of baseline tumor burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.008DOI Listing
February 2019
1 Read

Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-based Analysis.

Biol Blood Marrow Transplant 2019 Feb 12. Epub 2019 Feb 12.

Division of Hematology/Oncology, Hospital for Sick Children, Toronto, Ontario.

Introduction: Access to hematopoietic stem cell transplantation (HSCT) in pediatric acute lymphoblastic leukemia (ALL) is primarily dependent on disease-related factors but may be influenced by social and economic determinants.

Methods: We included all children < 15 years old with newly diagnosed ALL in Canada between 2001 and 2018 using the Cancer in Young People in Canada (CYP-C) national registry. We examined factors potentially associated with the likelihood of receiving HSCT using univariate and multivariable logistic regression models. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193013
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.02.009DOI Listing
February 2019
3 Reads

Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma.

Biol Blood Marrow Transplant 2019 Feb 11. Epub 2019 Feb 11.

Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX. Electronic address:

We analyzed 186 patients with lymphoma who received allogeneic stem cell transplant (ASCT) with fludarabine-melphalan (FM) conditioning and different donors [25 haploidentical (HD), 98 matched unrelated (MUD), and 63 matched related (MRD)] at our institution between 09/2009-01/2018. Patients received fludarabine 160 mg/m (40 mg/m/day x 4 days) in combination with one dose of melphalan 140 mg/m (FM140) or 100 mg/m2 (FM100). Engraftment was similar between the 3 groups (92%, 89%, and 98%, respectively; p=0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.002DOI Listing
February 2019
2 Reads

Survivor and Clinician Assessment of Survivorship Care Plans for Hematopoietic Stem Cell Transplant Patients: An Engineering, Primary Care, and Oncology Collaborative for Survivorship Health.

Biol Blood Marrow Transplant 2019 Feb 11. Epub 2019 Feb 11.

University of Wisconsin, Madison; University of Wisconsin Carbone Cancer Center. Electronic address:

Background: The long-term care of hematopoietic stem cell transplant (HSCT) survivors poses special challenges due to a myriad of possible chronic and/or late complications. Survivorship care plans (SCPs) have been proposed as a tool to communicate information regarding the late effects of treatment and recommended follow-up care to clinicians and survivors. Our primary objective was to determine SCP content and format as well as to assess preferred timing of SCP provision following HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.003DOI Listing
February 2019

New-onset post-transplant diabetes mellitus after allogeneic hematopoietic cell transplant is initiated by insulin resistance, not immunosuppressive medications.

Biol Blood Marrow Transplant 2019 Feb 6. Epub 2019 Feb 6.

Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

New-onset post-transplant diabetes mellitus (PTDM) occurs frequently following allogeneic hematopoietic cell transplant (HCT). Although calcineurin inhibitors and corticosteroids are assumed the cause for hyperglycemia, patients developing PTDM have elevated fasting C-peptide levels before HCT and prior to immunosuppressive medications. To determine if PTDM results from established insulin resistance present before transplant, we performed oral glucose tolerance tests (OGTT) and measured whole-body, peripheral, and hepatic insulin sensitivity with euglycemic hyperinsulinemic clamps before and 90 days after HLA-identical sibling donor HCT in 20 patients without pre-transplant diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.001DOI Listing
February 2019
2 Reads

Critical role of mismatched HLA in hemorrhagic cystitis after haploidentical hematopoietic stem cell transplant.

Biol Blood Marrow Transplant 2019 Feb 5. Epub 2019 Feb 5.

HSCT and Cell Therapy Unit, Banco de Sangre y Tejidos de Cantabria, Hospital de la Santa Cruz, B° Las Mazas17., 39120 Liencres (Cantabria), Phone: (34) 942202588, Fax: (34) 942355035. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.035DOI Listing
February 2019

Dynamics of the Gut Microbiota in Children Receiving Selective or Total Gut Decontamination Treatment During Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Feb 4. Epub 2019 Feb 4.

Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands; Center for Microbiome Analyses and Therapeutics, Leiden University Medical Center, Leiden, the Netherlands.

Bloodstream infections and Graft-versus-Host disease (GvHD) are common complications after hematopoietic stem cell transplantation (HSCT) procedures, associated with the gut microbiota which acts as a reservoir for opportunistic pathogens. Selective gut decontamination (SGD) and total gut decontamination (TGD) during HSCT have been associated with a decreased risk of developing these complications after transplantation. However, since studies have shown conflicting results, the use of these treatments remain subject of debate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.037DOI Listing
February 2019
1 Read

Glucagon-like peptide-1 is a marker of systemic inflammation in patients treated with high-dose chemotherapy and autologous stem cell transplantation.

Biol Blood Marrow Transplant 2019 Feb 4. Epub 2019 Feb 4.

Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark; Institute for Inflammation Research, University Hospital Rigshospitalet, Copenhagen, Denmark.

Autologous stem cell transplantation (ASCT) is challenged by side effects that may be propagated by chemotherapy-induced mucositis resulting in bacterial translocation and systemic inflammation. Since gastrointestinal damage appear as an early event in this cascade of reactions, we hypothesized that markers reflecting damage to the intestinal barrier could serve as early predictive markers of toxicity. Glucagon-like peptide-1 (GLP-1), a well-known regulator of blood glucose, has been found to promote intestinal growth and repair in animal studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.036DOI Listing
February 2019

The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time.

Biol Blood Marrow Transplant 2019 Feb 2. Epub 2019 Feb 2.

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address:

Bone marrow (BM) is an essential source of hematopoietic stem cell grafts for many allogeneic hematopoietic cell transplant (HCT) recipients, including adult patients (for specific diseases and transplantation strategies) and the majority of pediatric recipient. However, since the advent of granulocyte colony-stimulating factor-mobilized peripheral blood stem cell (PBSC) grafts, there has been a significant decrease in the use of BM in HCT, thought to be due mainly to the increased logistical challenges in harvesting BM compared with PBSCs, as well as generally no significant survival advantage of BM over PBSCs. The decreased frequency of collection has the potential to impact the quality of BM harvests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.034DOI Listing
February 2019

BEAM Vs BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN'S LYMPHOMA.

Biol Blood Marrow Transplant 2019 Feb 1. Epub 2019 Feb 1.

Division of Hematology, Dept. of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA. Electronic address:

High-dose chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT) is a standard of care for patients with relapsed Hodgkin's lymphoma (HL). Different conditioning regimen prior to AHSCT have been used with the two most common being BEAM (carmustine, etoposide, cytarabine, and melphalan) and BUCYVP16 (busulfan, cyclophosphamide, and etoposide). We retrospectively compared the outcomes of patients treated with BEAM (N=128) or BUCYVP16 (N=105) followed by AHSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.032DOI Listing
February 2019
3 Reads

Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.

Biol Blood Marrow Transplant 2019 Jan 31. Epub 2019 Jan 31.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Medical Oncology, Department of Medicine. Electronic address:

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal hematopoietic cell disease characterized by destruction of hematopoietic cells through the activation of the complement system with manifestations that can be life threatening including hemolysis, thrombosis, and marrow failure. Allogeneic hematopoietic cell transplantation (HCT) remains the only cure for PNH, but eculizumab, a terminal complement inhibitor of C5, has been used to prevent complement mediated hemolysis in PNH since its FDA approval in 2007. We examined outcomes of HCT in PNH patients to evaluate the effects of disease subtype, conditioning intensity, and eculizumab use either pre- or post-HCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.033DOI Listing
January 2019
2 Reads

Limited Utility of Outpatient Surveillance Blood Cultures in Hematopoietic Cell Transplant Recipients on High-Dose Steroids for Treatment of Acute Graft-versus-Host-Disease.

Biol Blood Marrow Transplant 2019 Jan 31. Epub 2019 Jan 31.

Department of Medicine, University of Washington School of Medicine, Seattle, WA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Infection Prevention, Seattle Cancer Care Alliance, Seattle, WA. Electronic address:

Background: Steroids used to treat acute graft-versus-host-disease (GVHD) are thought to blunt clinical symptoms of infection. We aimed to assess the value of weekly surveillance blood cultures (SBCs) drawn in an outpatient setting from hematopoietic cell transplant (HCT) patients receiving high-dose steroids. We hypothesized that most positive outpatient surveillance cultures would be low-pathogenicity gram positive organisms and would lead to excess vancomycin therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.031DOI Listing
January 2019

Effect of graft-versus-host disease prophylaxis regimens on T and B cell reconstitution after allogeneic hematopoietic stem cell transplantation.

Biol Blood Marrow Transplant 2019 Jan 30. Epub 2019 Jan 30.

Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; Department of Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden; Department of Applied Physics, Royal Institute of Technology, Stockholm, Sweden.

Lymphocyte reconstitution is pivotal for successful long-term outcome after allogeneic hematopoietic stem cell transplantation (HSCT), and conditioning and post-transplant immunosuppression constitute risk factors for prolonged immunodeficiency. Nevertheless, the effect of different immunosuppressive protocols on lymphocyte output and replicative capacity has not been investigated. Here, we assessed T-cell receptor excision circles (TREC), kappa-deleting recombination excision circles (KREC), and T-cell telomere length (TL) as proxy markers for immune reconstitution in patients in a prospective randomized trial comparing graft-versus-host disease (GVHD) prophylaxis after transplantation (cyclosporine/methotrexate vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.029DOI Listing
January 2019

Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation.

Biol Blood Marrow Transplant 2019 Jan 30. Epub 2019 Jan 30.

Department of Pediatrics, Michigan Medicine, University of Michigan, Ann Arbor, Michigan.

The overall composite of graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS), defined as survival free of grade III-IV acute GVHD (aGVHD), chronic GVHD (cGVHD) requiring systemic immunosuppressive therapy (IST), or relapse, has emerged as a useful composite in clinical trials and to capture clinically meaningful events that impact quantity and quality of survival after allogeneic hematopoietic cell transplantation (HCT). We reviewed 565 consecutive patients aged ≥18 years undergoing HCT for hematologic malignancy to analyze how baseline incidence, specifics of clinical definitions, and proposed reductions in any one individual event may dynamically alter the overall performance of the composite To determine the relative impact of each GRFS event (excluding death), we accounted for competing risks using Fine and Gray methods, and correlated each event with overall survival (OS) using Kaplan-Meier methods. The consequences of modulating individual or composite endpoints on OS, such as hypothesized reductions of events of an HCT interventional trial, were examined using Monte Carlo simulations. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193008
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.01.024DOI Listing
January 2019
2 Reads

Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Jan 30. Epub 2019 Jan 30.

Blood and Marrow Transplant Center, Florida Hospital Cancer Institute, Orlando, Florida. Electronic address:

Thrombocytopenia after allogeneic hematopoietic stem cell transplantation (allo-SCT) can pose significant problems in management of patients. Eltrombopag is a small-molecule thrombopoietin receptor agonist that has been approved for use in immune thrombocytopenic purpura and aplastic anemia; but its use after allo-SCT is limited. Between 2014 and 2017, we treated 13 patients with eltrombopag for poor platelet engraftment without evidence of relapse at the time of initiation, including 6 patients with primary platelet engraftment failure and 7 with secondary platelet engraftment failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.027DOI Listing
January 2019
1 Read
3.404 Impact Factor

Salivary Changes before and after Hematopoietic Stem Cell Transplantation: A Systematic Review.

Biol Blood Marrow Transplant 2019 Jan 30. Epub 2019 Jan 30.

Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

Severe oral problems, including oral mucositis (OM) and xerostomia, often occur after conditioning therapy for hematopoietic stem cell transplantation (HSCT). Saliva plays a major role in protecting the oral mucosa and teeth. Alterations in salivary flow rate or salivary components resulting in decreased salivary defence mechanisms may affect oral/mucosal health and may influence the severity of OM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.026DOI Listing
January 2019

Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies.

Biol Blood Marrow Transplant 2019 Jan 29. Epub 2019 Jan 29.

Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044 China. Electronic address:

Haploidentical transplantations have achieved comparable survival as HLA fully matched unrelated donors. When choosing the best donor for HLA-haploidentical transplantations, most institutions prioritize using young male donors over mother donors. In a retrospective study we compared outcomes in mother donor and unrelated donor transplantations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.030DOI Listing
January 2019
1 Read
3.404 Impact Factor

Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2019 Jan 30. Epub 2019 Jan 30.

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. Electronic address:

Although the use of geriatric assessment (GA) in the allogeneic hematopoietic cell transplantation (HCT) setting has been widely reported, few studies have evaluated the impact of patient-reported function on autologous HCT (autoHCT) outcomes. In this study, GA, including the administration of Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) quality of life tool, was performed in 184 patients age ≥50 years (median age, 61 years; range, 50 to 75 years) before autoHCT. Associations among GA findings, quality of life metrics, and post-transplantation outcomes were evaluated using Cox regression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.028DOI Listing
January 2019
1 Read

Post-allogeneic eculizumab as prophylaxis against hemolysis and thrombosis for patients with hematologic disorders associated with PNH clones.

Biol Blood Marrow Transplant 2019 Jan 29. Epub 2019 Jan 29.

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA; Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA.

Paroxysmal nocturnal hemoglobinuria (PNH) is frequently seen in the context of other aplastic anemia and myelodysplastic syndrome and is associated with hemolysis and increased thromboembolic events. Allogeneic hematopoietic stem cell transplantation (alloHCT) is the only curative treatment but is associated with significant morbidity. The terminal complement inhibitor eculizumab reduces hemolysis and thromboembolic events and is the only FDA-approved therapy for PNH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.025DOI Listing
January 2019
1 Read

T Cell Repertoire Evolution after Allogeneic Bone Marrow Transplantation: An Organizational Perspective.

Biol Blood Marrow Transplant 2019 Jan 21. Epub 2019 Jan 21.

Bone Marrow Transplant Program, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. Electronic address:

High-throughput sequencing (HTS) of human T cell receptors has revealed a high level of complexity in the T cell repertoire, which makes it difficult to correlate T cell reconstitution with clinical outcomes. The associations identified thus far are of a broadly statistical nature, precluding precise modeling of outcomes based on T cell repertoire development following bone marrow transplantation (BMT). Previous work has demonstrated an inherent, mathematically definable order observed in the T cells from a diverse group of donors, which is perturbed in recipients following BMT. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193007
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.01.021DOI Listing
January 2019
2 Reads

αβ T Cell-Depleted Haploidentical Hematopoietic Stem Cell Transplantation without Antithymocyte Globulin in Children with Chemorefractory Acute Myelogenous Leukemia.

Biol Blood Marrow Transplant 2019 Jan 21. Epub 2019 Jan 21.

Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia. Electronic address:

We evaluated the outcome of αβ T cell-depleted haploidentical hematopoietic stem cell transplantation (HSCT) in a cohort of children with chemorefractory acute myelogenous leukemia (AML). Twenty-two patients with either primary refractory (n = 10) or relapsed refractory (n = 12) AML in active disease status received a transplant from haploidentical donors. The preparative regimen included cytoreduction with fludarabine and cytarabine and subsequent myeloablative conditioning with treosulfan and thiotepa. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193007
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.01.023DOI Listing
January 2019
8 Reads

The Ex Vivo Treatment of Donor T Cells with Cosalane, an HIV Therapeutic and Small-Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplantation Models.

Biol Blood Marrow Transplant 2019 Jan 19. Epub 2019 Jan 19.

Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Internal Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address:

Despite recent advances in therapy, allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative option for a range of high-risk hematologic malignancies. However, acute graft-versus-host disease (aGVHD) continues to limit the long-term success of HSCT, and new therapies are still needed. We previously demonstrated that aGVHD depends on the ability of donor conventional T cells (T) to express the lymph node trafficking receptor, CC-Chemokine Receptor 7 (CCR7). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193007
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.01.022DOI Listing
January 2019
3 Reads

High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.

Biol Blood Marrow Transplant 2019 Jan 18. Epub 2019 Jan 18.

Department of Oncology/Hematology, Shimane University Hospital, Izumo, Japan.

High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) has been shown to improve the prognosis of patients with central nervous system (CNS) lymphoma. We queried the Japan Society for Hematopoietic Cell Transplantation Registry for 2006 to 2015 to analyze the outcomes of 102 patients with primary CNS lymphoma (PCNSL) who underwent first HDT/ASCT. The median patient age was 54 years (range, 20 to 74 years), and 65 patients were treated in an upfront setting. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193007
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.01.020DOI Listing
January 2019
13 Reads

Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies.

Biol Blood Marrow Transplant 2019 Feb 26;25(2):e60-e64. Epub 2018 Oct 26.

Weill Cornell Medicine, New York, New York. Electronic address:

Donor-specific HLA antibodies (DSAs) have been associated with an increased risk of graft failure. To decrease DSA levels and reduce the risk of graft failure in haploidentical cord blood transplantation recipients, we studied the effect of bortezomib (BTZ) and i.v. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183065
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.10.018DOI Listing
February 2019
4 Reads

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Jan 17. Epub 2019 Jan 17.

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

The clinical significance of extramedullary relapse (EMR) of acute myelogenous leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains poorly defined. Here we report the clinical outcomes of patients who underwent allo-HSCT for AML at our institution between 2000 and 2012. A total of 293 patients with AML who underwent allo-HSCT were included. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193002
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.01.011DOI Listing
January 2019
6 Reads

Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study.

Biol Blood Marrow Transplant 2019 Jan 18. Epub 2019 Jan 18.

Institute of Hematology L. and A Seràgnoli, Sant'Orsola Malpighi University Hospital, Bologna, Italy.

Veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a life-threatening complication affecting patients undergoing hematopoietic stem cell transplantation (HSCT). The survival rate is higher when specific therapy is initiated early; thus, improving early, noninvasive diagnosis of VOD/SOS is an important need. In an adult population undergoing HSCT, we aimed to assess the role of liver stiffness measurement (LSM), evaluated by transient elastography (TE), for diagnosing VOD/SOS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.019DOI Listing
January 2019
3 Reads

Role of Physical Therapy before and after Hematopoietic Stem Cell Transplantation: White Paper Report.

Biol Blood Marrow Transplant 2019 Jan 15. Epub 2019 Jan 15.

Physical Therapy Association for Graft Versus Host Disease, Swindon, United Kingdom; Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; Department of Medicine, Mayo Clinic, Rochester, Minnesota.

Hematopoietic stem cell transplantation (HSCT) patients can suffer from various musculoskeletal problems resulting in long-term functional incapacity. Physical therapy (PT), as a part of the healthcare team, has been historically advocated for regaining functional capacity and improving quality of life post-HSCT. Because of the nature of this condition and the burden of post-transplant complications, this patient group requires a unique approach toward their rehabilitation that takes into account their complex musculoskeletal presentation ranging from fascia, muscle, tendons, bones, and ligaments. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193006
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.01.018DOI Listing
January 2019
15 Reads

Comparison of Outcomes of Frontline Immunosuppressive Therapy and Frontline Haploidentical Hematopoietic Stem Cell Transplantation for Children with Severe Aplastic Anemia Who Lack an HLA-Matched Sibling Donor.

Biol Blood Marrow Transplant 2019 Jan 15. Epub 2019 Jan 15.

Department of Hematology, People's Hospital of Zhengzhou University, Henan, China. Electronic address:

We compared the outcomes of immunosuppressive therapy (IST) with those of T cell-replete haploidentical donor hematopoietic stem cell transplantation (haplo-HSCT) in children and adolescents with severe aplastic anemia (SAA). The medical records of 49 patients with SAA who received frontline IST (n = 29) or frontline haplo-HSCT (n = 20) between 2012 and 2016 were analyzed retrospectively. Fourteen patients responded after the first IST, and 1 patient responded after the second IST in the frontline IST group; 12 patients underwent salvage HSCT after IST failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.017DOI Listing
January 2019
7 Reads

Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Jan 15. Epub 2019 Jan 15.

Department of Internal Medicine IV, Hematology and Oncology, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Halle, Germany.

The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) in the treatment of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) relies mainly on the graft-versus-leukemia effect. Relapse after allo-HCT occurs in a considerable proportion of patients and has a dismal prognosis, with still very limited curative potential. This review provides an overview of the established and evolving approaches to preventing or treating relapse of AML and MDS after allo-HCT, in the context of novel insight into the biology of relapse. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193006
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.01.016DOI Listing
January 2019
4 Reads

Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.

Biol Blood Marrow Transplant 2019 Jan 14. Epub 2019 Jan 14.

Messner Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

Allogeneic hematopoietic cell transplantation (HCT) is potentially curative for acute myelogenous leukemia (AML); however, a major cause of treatment failure is disease relapse. The purpose of this single-center Phase I study was to determine the safety and tolerability of administration of the CXCR4 inhibitor plerixafor (Mozobil; Sanofi Genzyme) along with myeloablative conditioning in patients with AML undergoing allogeneic HCT. The rationale was that plerixafor may mobilize leukemic stem cells, making them more susceptible to the conditioning chemotherapy (registered at ClinicalTrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.014DOI Listing
January 2019
2 Reads

Consider Allogeneic Bone Marrow Transplantation for Older, Fit Patients with Aplastic Anemia.

Authors:
George E Georges

Biol Blood Marrow Transplant 2019 Jan 11. Epub 2019 Jan 11.

Fred Hutchison Cancer Research Center, Seattle, Washington; University of Washington, Seattle, Washington. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.015DOI Listing
January 2019
1 Read

Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601.

Biol Blood Marrow Transplant 2019 Jan 11. Epub 2019 Jan 11.

Dept. of Pediatrics, Division of Hematology and Oncology, Washington University School of Medicine, St. Louis Children's Hospital, St Louis, Missouri.

Stroke and cognitive decline are hallmarks of sickle cell disease (SCD). The natural history of SCD predicts progressive loss of 1 IQ point per year attributable to disease-related pathology. Hematopoietic cell transplantation (HCT) is curative by reverting to donor-derived erythropoiesis, but evidence that HCT can positively influence disease-induced cognitive decline is lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.008DOI Listing
January 2019
2 Reads

Comparable Outcome with a Faster Engraftment of Optimized Haploidentical Hematopoietic Stem Cell Transplantation Compared with Transplantations from Other Donor Types in Pediatric Acquired Aplastic Anemia.

Biol Blood Marrow Transplant 2019 Jan 11. Epub 2019 Jan 11.

Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center Children's Hospital, Seoul, Korea.

Haploidentical family donors have been used as an alternative source in hematopoietic cell transplantation for patients with severe aplastic anemia. We evaluated and compared the outcomes of transplantation in pediatric acquired severe aplastic anemia based on donor type. Sixty-seven patients who underwent transplantation between 1998 and 2017 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.010DOI Listing
January 2019
2 Reads

Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.

Biol Blood Marrow Transplant 2019 Jan 11. Epub 2019 Jan 11.

Department of Medicine, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts; Stem Cell Transplant Program, Section of Hematology and Oncology, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts. Electronic address:

In immunoglobulin light-chain (AL) amyloidosis, the depth of hematologic response to treatment is associated with improved survival and organ responses. We conducted a clinical trial using bortezomib in induction and in conditioning with melphalan before stem cell transplantation (SCT) for AL amyloidosis. The results of this clinical trial with a median follow-up of 36 months have been reported previously. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.007DOI Listing
January 2019
1 Read

Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.

Biol Blood Marrow Transplant 2019 Jan 11. Epub 2019 Jan 11.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for patients with multiple myeloma, as it provides a graft-versus-myeloma effect alongside a myeloma-free graft. Although reduced-intensity conditioning regimens decrease nonrelapse mortality (NRM), there is a paucity of data with regard to the ideal conditioning regimen in myeloma. We conducted a retrospective comparison of 3 different preparative regimens used for allo-HCT for multiple myeloma at our institution in recent clinical trials: busulfan/fludarabine (BuFlu), fludarabine/melphalan 100 mg/m (FM100), and fludarabine/melphalan 140 mg/m (FM140). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193002
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.01.009DOI Listing
January 2019
7 Reads

Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Jan 10. Epub 2019 Jan 10.

Department of Hematology, Hospital Universitari i Politècnic la Fe, Valencia. Spain; Centro de Investigación Biomédica en Red Cáncer, Instituto Carlos III, Madrid, Spain. Electronic address:

The current study evaluates the clinical effect of sirolimus exposure on the occurrence of cytomegalovirus (CMV) DNAemia necessitating preemptive antiviral therapy. A total of 167 consecutive recipients of reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT) who received sirolimus- and tacrolimus-based graft-versus-host disease (GVHD) prophylaxis and whose CMV serostatus was positive for donors and/or recipients were included in this multicenter retrospective study. A parametric model with consecutive sirolimus blood levels describing the time to CMV DNAemia-RAT was developed using NONMEM version 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.012DOI Listing
January 2019
2 Reads

Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.

Biol Blood Marrow Transplant 2019 Jan 11. Epub 2019 Jan 11.

Dana-Farber Cancer Institute, Boston, Massachusetts, United States. Electronic address:

Transplantation-associated thrombotic microangiopathy (TA-TMA) is a known complication of autologous hematopoietic cell transplantation (aHCT), particularly in children with neuroblastoma. We describe a pediatric single-institution experience of TA-TMA after aHCT. Data were abstracted from the medical record of patients who underwent aHCT between January 1, 2008, and July 1, 2018, at Boston Children's Hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.12.840DOI Listing
January 2019
2 Reads

Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia.

Biol Blood Marrow Transplant 2019 Jan 11. Epub 2019 Jan 11.

Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

After allogeneic stem cell transplantation (alloSCT), several immune checkpoints play an important role in the antileukemic immune response in the bone marrow (BM) microenvironment. However, immune checkpoint expression levels in the BM have not been reported after alloSCT in patients with acute myeloid leukemia (AML). We investigated the clinical impact of immune checkpoint expression in BM samples after alloSCT for AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.013DOI Listing
January 2019
2 Reads

The Prognostic Impact of Pretransplantation Inflammatory and Nutritional Status in Adult Patients after Myeloablative Single Cord Blood Transplantation.

Biol Blood Marrow Transplant 2019 Jan 11. Epub 2019 Jan 11.

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Markers of inflammatory and nutritional status, such as the Controlling Nutritional Status (CONUT) score, Prognostic Nutritional Index, Glasgow Prognostic Score, and C-reactive protein-albumin ratio (CAR) has been demonstrated to be associated with poor prognosis in patients with various cancers. Although the relatively low cell dose of a single cord blood unit restricts the indication for cord blood transplantation (CBT) to pediatric and relatively smaller and lighter adult patients, the impact of malnutrition on outcomes after CBT is unclear. We retrospectively analyzed 165 adult patients who underwent myeloablative single-unit CBT in our institute. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.006DOI Listing
January 2019
1 Read

Reply: Letter to the Editor Regarding "Autologous Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis".

Biol Blood Marrow Transplant 2019 Jan 8. Epub 2019 Jan 8.

Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel; Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel; Internal Medicine "A", Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.12.837DOI Listing
January 2019
1 Read

Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.

Biol Blood Marrow Transplant 2019 Jan 6. Epub 2019 Jan 6.

Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:

Mutational profiling has demonstrated utility in predicting the likelihood of disease progression in patients with myelofibrosis (MF). However, there is limited data regarding the prognostic utility of genetic profiling in MF patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT). We performed high-throughput sequencing of 585 genes on pre-transplant samples from 101 patients with MF who underwent allo-HCT and evaluated the association of mutations and clinical variables with transplantation outcomes. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193000
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.01.002DOI Listing
January 2019
4 Reads